Loss-of-function mutations in TSC1/2 were found in approximately 20% of patients with HCC, which serves as another major suppressor of the EGFR/PI3K/AKT/mTOR signaling pathway [30]. This evidence concerns the gene EGFR and hepatocellular carcinoma.